SuperworthNatures Sunshine Products profit margin NATR
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 3.7%
- Operating margin, 12 months
- 6.0%
- Net margin on a year earlier
- +0.6 pts
- Peer median
- 15.7%
Over the twelve months to Jun 30, 2026, Natures Sunshine Products kept 3.7% of its revenue as net profit, with an operating margin of 6.0% and a gross margin of 73.2%.
Five years earlier its net margin was 5.6%.
The median for 10 large drugmakers of a similar size is 15.7%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 4.1% | 5.2% | 72.4% |
| FY2024 | 1.7% | 4.4% | 71.5% |
| FY2023 | 3.4% | 4.2% | 72.1% |
| FY2022 | −0.1% | 3.9% | 71.0% |
| FY2021 | 6.5% | 7.8% | 74.0% |
| FY2020 | 5.5% | 5.6% | 73.7% |
| FY2019 | 1.9% | 4.5% | 74.1% |
| FY2018 | −0.2% | 1.5% | 73.8% |
| FY2017 | −3.8% | 0.4% | 73.4% |
| FY2016 | 0.6% | 2.9% | 73.3% |
| FY2015 | 4.5% | 4.3% | 73.7% |
| FY2014 | 2.7% | 5.2% | 75.0% |
| FY2013 | 4.8% | 6.4% | 75.0% |
| FY2012 | 6.9% | 9.3% | 74.6% |
| FY2011 | 4.8% | 5.5% | 75.7% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 3.7% | +0.6 pts | 6.0% | |
| Q1 FY26 | 4.1% | +1.8 pts | 5.7% | |
| Q4 FY25 | 4.1% | +2.4 pts | 5.2% | |
| Q3 FY25 | 3.2% | −0.6 pts | 5.1% | |
| Q2 FY25 | 3.1% | −0.4 pts | 4.4% | |
| Q1 FY25 | 2.2% | −1.5 pts | 4.7% | |
| Q4 FY24 | 1.7% | −1.7 pts | 4.4% | |
| Q3 FY24 | 3.8% | +2.0 pts | 4.8% | |
| Q2 FY24 | 3.5% | +2.3 pts | 4.9% | |
| Q1 FY24 | 3.7% | +2.9 pts | 5.2% | |
| Q4 FY23 | 3.4% | +3.5 pts | 4.2% | |
| Q3 FY23 | 1.8% | −0.7 pts | 3.9% |
Against its peers
Companies in Drug Manufacturers - General nearest Natures Sunshine Products' size, closest first, today.
| Company | Profit margin |
|---|---|
| NATRNatures Sunshine Products | 3.7% |
| ARVNArvinas | 2.9% |
| PBYIPuma Biotechnology | 11.6% |
| IRWDIronwood Pharmaceuticals | 33.4% |
| ZVRAZevra Therapeutics | 42.8% |
| CRMDCorMedix | 40.5% |
| LFVNLifevantage | 2.8% |
| SPROSpero Therapeutics | 15.7% |
| COLLCollegium Pharmaceutical | 5.9% |
| ABUSArbutus Biopharma | 84.2% |
| ATNMActinium Pharmaceuticals | n/m |
| Peer median | 15.7% |
Where Natures Sunshine Products ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Natures Sunshine Products
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.